Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
+$0.14 today
- Market cap
- $3.42B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
Volume 1.51M
Average 1.21M
AMLX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 6.6% from a year ago
Cash & equivalents stood at $240.1M at the end of Q3 FY2026, up 6.6% from a year earlier and up 386.8% from the prior quarter. Over 3 fiscal years it compounded at +53.6% a year.
Context
- Cash & equivalents amounted to 30.5% of total assets at the end of Q3 FY2026, down 31.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +6.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 226.65M USD
- Year-over-year change
- +192.9%
- 4-year CAGR
- +45.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 226.65M | +192.9% |
| FY2024 | 2024-12-31 | 77.39M | -54.5% |
| FY2023 | 2023-12-31 | 170.2M | +172.2% |
| FY2022 | 2022-12-31 | 62.53M | +24.6% |
| FY2021 | 2021-12-31 | 50.19M | — |
Cash & Equivalents vs competitors
How AMLX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +6.6% is the 5th highest of 10, against a peer median of -4.0%.
- Cash & equivalents amounts to 30.5% of total assets for AMLX, versus a peer median of 27.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $361.85M USD | +142.0% | +79.7% | 27.6% | |
| Mar 2026 | $329.46M USD | -21.2% | -24.4% | 94.2% | |
| Sep 2026 | $296.3M USD | -12.4% | +10.4% | 10.2% | |
| Sep 2026 | $240.1M USD | +6.6% | +53.6% | 30.5% | |
| Jun 2026 | $201.53M USD | +42.7% | -2.0% | 17.4% | |
| Dec 2025 | $131.75M USD | +9.1% | -11.7% | 99.1% | |
| Jun 2026 | $53.43M USD | +1084.7% | -17.0% | 94.2% | |
| Mar 2026 | CHF 19.17M CHF | -4.0% | -5.3% | 13.9% | |
| Mar 2026 | $6.15M USD | -27.6% | -26.1% | 4.2% | |
| Mar 2026 | $5.94M USD | -39.6% | -34.3% | 27.4% | |
| Peer median (excluding AMLX) | — | -4.0% | -11.7% | 27.4% | |
Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 50.19M | 62.53M | 170.2M | 77.39M | 226.65M |
| Short-term Investments | 45.93M | 284.42M | 201.16M | 99.11M | 90.33M |
| Net Receivables | 0 | 15.31M | 40.05M | 447K | 88K |
| Inventory | 0 | 9.77M | 38.32M | 0 | 0 |
| Other Current Assets | 3.44M | 10.11M | 14.93M | 12.48M | 6.6M |
| Total Current Assets | 104.95M | 382.13M | 464.67M | 189.43M | 323.67M |
| Property, Plant & Equipment (Net) | 474K | 8.14M | 6.41M | 2.73M | 5.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 189K | 1.19M | 46.38M | 1.47M | 3.48M |
| Total Non-current Assets | 663K | 9.32M | 52.79M | 4.2M | 8.97M |
| Total Assets | 105.61M | 391.45M | 517.45M | 193.63M | 332.65M |
| Account Payables | 4.37M | 6.26M | 22.06M | 2.94M | 3.52M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.28M | 15.23M | 40.93M | 9.99M | 10.06M |
| Total Current Liabilities | 17.4M | 46.61M | 82.04M | 28.41M | 22.69M |
| Long-term Debt | 0 | 0 | 0 | 0 | 4.7M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 239.39M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 239.39M | 4.24M | 1.98M | 463K | 4.7M |
| Total Liabilities | 256.78M | 50.85M | 84.02M | 28.87M | 27.39M |
| Common Stock | 1K | 7K | 7K | 7K | 11K |
| Retained Earnings | (155.85M) | (354.22M) | (304.95M) | (606.69M) | (751.43M) |
| Accumulated OCI | 9K | (86K) | 197K | (92K) | 404K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (151.17M) | 340.61M | 433.43M | 164.77M | 305.26M |
| Total Debt | 0 | 6.28M | 4.24M | 1.98M | 5.96M |
| Net Debt | (50.19M) | (56.25M) | (165.96M) | (75.41M) | (220.69M) |
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
Intrinsic Alpha fair value
Locked
Current Price
$26.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.